gavilimomab

mAbexperimental

Gavilimomab is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147. Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy. — Wikipedia

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Oct 1, 1999 (NCT00035880)

Timeline

1990s

Jan 1, 1999
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Graft vs Host Disease · Phase 2/Phase 3

Mechanism of action

BasiginINHIBITOR
BSG inhibitor
- Basigin (BSG) ↗
BasiginOTHER
BSG other
Depletes activated T cells (CD4+ and CD8+) and B cells via a complement-dependent cytotoxic mechanism, while resting lymphocytes are unaffected.
- Basigin (BSG) ↗

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

Parenteral

Topical

Sources

WikipediaGavilimomab ↗
ChEMBLCHEMBL2109193 ↗

Also known as

abx-cbl
abx-cbl
gavilimomab

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00035880	Phase 2/Phase 3 (Phase 3)	Oct 1, 1999	Abgenix, Sangstat Medical Corporation

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Abgenix	For profit	1	1	1	1999
Sangstat Medical Corporation	For profit	1	0	1	1999

2 organizations

Page 1 / 1